Oncopeptides AB logo

ONCO - Oncopeptides AB Share Price

SEK138.7 -1.7  -1.2%

Last Trade - 22/05/20

Mid Cap
Market Cap £655.4m
Enterprise Value £577.0m
Revenue £n/a
Position in Universe 321st / 1748
Unlock ONCO Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2019, Oncopeptides AB revenues was not reported. Net loss increased 80% to SEK740.7M. Higher net loss reflects Research and development costs increase of 75% to SEK548.3M (expense), Marketng and distributon costs increase from SEK51.1M to SEK127.4M (expense), Administratve expenses increase of 30% to SEK72M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ONCO Revenue Unlock ONCO Revenue

Net Income

ONCO Net Income Unlock ONCO Revenue

Normalised EPS

ONCO Normalised EPS Unlock ONCO Revenue

PE Ratio Range

ONCO PE Ratio Range Unlock ONCO Revenue

Dividend Yield Range

ONCO Dividend Yield Range Unlock ONCO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ONCO EPS Forecasts Unlock ONCO Revenue
Profile Summary

Oncopeptides AB is a Sweden-based clinical development pharmaceutical company, which is primarily engaged in the healthcare industry. The Company focuses on research and development of cancer treatment solutions. The Company's product Ygalo is a peptidase potentiated alkylator, a type of cytotoxic drug that is targeted for use in the treatment of multiple myeloma. Ygalo is an alkylating agent that leverages the overrepresentation of peptidase enzymes in cancer cells to rise the concentration of active cancer fighting molecules in myeloma cells. Ygalo is intended for the treatment of patients with late-stage relapsed and refractory multiple myeloma. Ygalo is administered intravenously and is transported into cells where it is cleaved by peptidase enzymes, which impair transport of its active cancer-fighting agents out of the cell at the same time as driving more Ygalo into the cell.

Last Annual December 31st, 2019
Last Interim December 31st, 2019
Public Since February 22, 2017
No. of Shareholders: n/a
No. of Employees: 88
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 55,413,417
Free Float (0.0%)
Eligible for
ONCO Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ONCO
Upcoming Events for ONCO
Similar to ONCO
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.